Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 19:43:57 Source:worldViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Children are evacuated from school 'during an exam' after threat made via email
Next:Why US Catholics are planning pilgrimages in communities across the nation
You may also like
- I was 'brokefished' by my friend for £400
- Hannah Waddingham reflects on end of Ted Lasso and friendship with Jason Sudeikis
- Ukraine starts building 2 modern units at Khmelnytskyi nuclear plant
- Closing prices for crude oil, gold and other commodities
- Children are evacuated from school 'during an exam' after threat made via email
- More human remains believed those of missing woman wash up on beach
- Dubai rain: Emirates again halts local flight check
- Cloud seeding is used around the WORLD
- Amir Khan's £11.5m luxury wedding venue finally hosts its first marriage: Bride arrives on horse